{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:05Z","timestamp":1791908645086,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jgo.2024.102148","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T20:11:37Z","timestamp":1737403897000},"page":"102148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Charles E.","family":"Gaber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebere","family":"Okpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah I.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmoy","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Reizine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jgo.2024.102148_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2024.102148_bb0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2024.102148_bb0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jgo.2024.102148_bb0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jgo.2024.102148_bb0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy. Cabot RC, Harris NL, Rosenberg ES, et al., eds","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2024.102148_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100887","article-title":"Cardiovascular toxicities associated with abiraterone compared to enzalutamide\u2013a pharmacovigilance study","volume":"36","author":"Cone","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jgo.2024.102148_bb0040","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.clgc.2024.102066","article-title":"Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials","author":"Zhou","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pros.24096","article-title":"Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: a real-world evidence study","volume":"81","author":"Liu","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.jgo.2024.102148_bb0050","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2024.102148_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate Cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jgo.2024.102148_bb0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.jgo.2024.102148_bb0065","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.jgo.2024.102148_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jgo.2024.102148_bb0075","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jgo.2024.102148_bb0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.bjc.6604201","article-title":"Clinical pharmacology of cancer therapies in older adults","volume":"98","author":"Hurria","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2014.0009","article-title":"Senior adult oncology, version 2.2014","volume":"12","author":"Hurria","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jgo.2024.102148_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221149887","article-title":"Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global young International Society of Geriatric Oncology drug review","volume":"15","author":"Mir","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jgo.2024.102148_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2024.102148_bb0105","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"issue":"55","key":"10.1016\/j.jgo.2024.102148_bb0110","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"8","key":"10.1016\/j.jgo.2024.102148_bb0115","doi-asserted-by":"crossref","first-page":"379.e17","DOI":"10.1016\/j.urolonc.2022.05.025","article-title":"Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: a population-based study using the SEER-Medicare linked dataset","volume":"40","author":"Kwon","year":"2022","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.102148_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101520","article-title":"Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer","volume":"14","author":"Deol","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102148_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5772","article-title":"Comparing the Centers for Medicare and Medicaid Services (CMS) enrollment data death dates to the National Death Index (NDI)","volume":"33","author":"Pennap","year":"2024","journal-title":"Pharmacoepidemiol Drug"},{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102148_bb0140","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ijc.34348","article-title":"Long-term use and risk of major adverse cardiac events: comparing enzalutamide and abiraterone in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer","volume":"152","author":"Chen","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jgo.2024.102148_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/1651-226X.2024.20337","article-title":"Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide","volume":"63","author":"Baser","year":"2024","journal-title":"AO"},{"key":"10.1016\/j.jgo.2024.102148_bb0150","article-title":"Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study","author":"Lee","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.jgo.2024.102148_bb0155","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol"},{"issue":"8","key":"10.1016\/j.jgo.2024.102148_bb0160","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol"},{"issue":"8","key":"10.1016\/j.jgo.2024.102148_bb0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M19-3261","article-title":"Relationship of a claims-based frailty index to annualized medicare costs: a cohort study","volume":"172","author":"Johnston","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgo.2024.102148_bb0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2022.06.031","article-title":"The role of frailty on surgical outcomes following pelvic organ prolapse surgery in medicare beneficiaries: a national study","volume":"168","author":"Reddy","year":"2022","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.jgo.2024.102148_bb0175","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/jgs.17002","article-title":"Changes in a frailty index and association with mortality","volume":"69","author":"Shi","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.jgo.2024.102148_bb0180","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.jgo.2024.102148_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034529","article-title":"Frailty and clinical outcomes of Ticagrelor versus Clopidogrel in older adults with acute myocardial infarction","volume":"13","author":"Ko","year":"2024","journal-title":"JAHA"},{"key":"10.1016\/j.jgo.2024.102148_bb0190","doi-asserted-by":"crossref","DOI":"10.1093\/gerona\/glae094","article-title":"Claims-based frailty index and its relationship with commonly used clinical frailty measures","author":"Sison","year":"2024","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"10.1016\/j.jgo.2024.102148_bb0195","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"25","key":"10.1016\/j.jgo.2024.102148_bb0200","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jgo.2024.102148_bb0205","article-title":"Optimizing large real-world data analysis with parquet files in R: A step-by-step tutorial","author":"Abdelaziz","year":"2023","journal-title":"Pharmacoepidemiol Drug"},{"issue":"10","key":"10.1016\/j.jgo.2024.102148_bb0210","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"key":"10.1016\/j.jgo.2024.102148_bb0215","author":"Griefer"},{"key":"10.1016\/j.jgo.2024.102148_bb0220","doi-asserted-by":"crossref","DOI":"10.4137\/CMO.S13671","article-title":"Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel\u2014an indirect comparison","volume":"8","author":"Tan","year":"2014","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.jgo.2024.102148_bb0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2021.05.003","article-title":"Effectiveness of first-line abiraterone versus enzalutamide among patients \u226580 years of age with metastatic castration-resistant prostate cancer: a retrospective propensity score\u2013weighted comparative cohort study","volume":"152","author":"Soleimani","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2024.102148_bb0230","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","article-title":"Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","volume":"24","author":"Tagawa","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.jgo.2024.102148_bb0235","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jgo.2024.102148_bb0240","article-title":"Comparative effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2024.102148_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00816-0","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer","author":"George","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/aje\/kwaa190","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 french population study (the SPEAR cohort)","volume":"190","author":"Scailteux","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.jgo.2024.102148_bb0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0260","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.jgo.2024.102148_bb0270","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clgc.2023.07.003","article-title":"Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate cancer: a disproportionality analysis based on the FDA adverse event reporting system (FAERS)","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2024.102148_bb0275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41391-019-0182-x","article-title":"Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies","volume":"23","author":"De Nunzio","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.jgo.2024.102148_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100261","article-title":"Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients","volume":"6","author":"Kulkarni","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.jgo.2024.102148_bb0285","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai","year":"2022","journal-title":"JNCI"},{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0290","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bcp.14972","article-title":"Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients","volume":"88","author":"Scailteux","year":"2022","journal-title":"Brit J Clinical Pharma"},{"issue":"4","key":"10.1016\/j.jgo.2024.102148_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jgo.2024.102148_bb0300","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jclinepi.2018.06.009","article-title":"Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials","volume":"103","author":"Murray","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.jgo.2024.102148_bb0305","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/pds.4396","article-title":"Position matters: validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study","volume":"27","author":"Bush","year":"2018","journal-title":"Pharmacoepidemiol Drug"},{"issue":"1","key":"10.1016\/j.jgo.2024.102148_bb0310","first-page":"e18","article-title":"Accuracy of administrative databases in identifying patients with hypertension","volume":"1","author":"Tu","year":"2007","journal-title":"Open Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.102148_bb0315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2024.102148_bb0320","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The vulnerable elders survey: a tool for identifying vulnerable older people in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"14","key":"10.1016\/j.jgo.2024.102148_bb0325","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/cncr.33523","article-title":"Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor\u2013targeted therapy for metastatic castration-resistant prostate cancer","volume":"127","author":"Alibhai","year":"2021","journal-title":"Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824004211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824004211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:42:55Z","timestamp":1741131775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406824004211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1879406824004211"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102148","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102148"}}